Literature DB >> 19355842

Advances in Alzheimer therapy: understanding pharmacological approaches to the disease.

Ana Martínez, Debomoy K Lahiri, Ezio Giacobini, Nigel H Greig.   

Abstract

Although significant accomplishments have been made in research to understand, diagnose and treat Alzheimer's disease (AD) and its prequel, mild cognitive impairment, over the last two decades, a huge amount more remains to be achieved to impact this incurable, terminal disease that afflicts an estimated 26.6 million people worldwide. Increasing evidence indicates that early diagnosis will be fundamental to maximizing treatment benefits. Moreover, mechanistically-based, hypothesis-driven treatment strategies are now emerging to hopefully spearhead future therapy. The crossfertilization of ideas from multiple disciplines will prove key to optimize strategies and translate them to meaningful clinical utility, and forms the basis of the current issue focused on "Advances in Alzheimer therapy".

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19355842      PMCID: PMC5189685          DOI: 10.2174/156720509787602924

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  7 in total

Review 1.  Editorial: advances in Alzheimer therapy: something old, something new, something borrowed, something blue.

Authors:  Nigel H Greig; Debomoy K Lahiri; Ezio Giacobini
Journal:  Curr Alzheimer Res       Date:  2005-07       Impact factor: 3.498

2.  Advances in Alzheimer therapy: development of innovative new strategies.

Authors:  Nigel H Greig; Ezio Giacobini; Debomoy K Lahiri
Journal:  Curr Alzheimer Res       Date:  2007-09       Impact factor: 3.498

Review 3.  Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.

Authors:  Robert E Becker; Nigel H Greig
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

4.  Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices?

Authors:  Robert E Becker; Nigel H Greig
Journal:  J Clin Psychopharmacol       Date:  2009-02       Impact factor: 3.153

Review 5.  Alzheimer's disease drug development: old problems require new priorities.

Authors:  Robert E Becker; Nigel H Greig
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-12       Impact factor: 4.388

Review 6.  Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.

Authors:  Parminder Raina; Pasqualina Santaguida; Afisi Ismaila; Christopher Patterson; David Cowan; Mitchell Levine; Lynda Booker; Mark Oremus
Journal:  Ann Intern Med       Date:  2008-03-04       Impact factor: 25.391

Review 7.  Resurrecting clinical pharmacology as a context for Alzheimer disease drug development.

Authors:  Robert E Becker; Latha K Unni; Nigel H Greig
Journal:  Curr Alzheimer Res       Date:  2009-02       Impact factor: 3.498

  7 in total
  2 in total

1.  Does EEG montage influence Alzheimer's disease electroclinic diagnosis?

Authors:  L R Trambaiolli; A C Lorena; F J Fraga; P A M K Kanda; R Nitrini; R Anghinah
Journal:  Int J Alzheimers Dis       Date:  2011-05-02

2.  DL0410 Ameliorates Memory and Cognitive Impairments Induced by Scopolamine via Increasing Cholinergic Neurotransmission in Mice.

Authors:  Wenwen Lian; Jiansong Fang; Lvjie Xu; Wei Zhou; Wandi Xiong; Hao Jia; Ai-Lin Liu; Guan-Hua Du
Journal:  Molecules       Date:  2017-03-06       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.